Telix pharmaceutical/$TLX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Telix pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Primary listing
Industry
Biotechnology
Headquarters
North Melbourne, Australia
Employees
423
ISIN
US87961M1053
Website
TLX Metrics
BasicAdvanced
$5.5B
173.78
$0.09
2.43
-
Price and volume
Market cap
$5.5B
Beta
2.43
52-week high
$30.36
52-week low
$13.61
Average daily volume
36K
Financial strength
Current ratio
2.776
Quick ratio
2.598
Long term debt to equity
98.548
Total debt to equity
102.329
Interest coverage (TTM)
11.30%
Profitability
EBITDA (TTM)
57.508
Gross margin (TTM)
61.79%
Net profit margin (TTM)
6.37%
Operating margin (TTM)
10.46%
Effective tax rate (TTM)
10.95%
Revenue per employee (TTM)
$1,214,740
Management effectiveness
Return on assets (TTM)
5.33%
Return on equity (TTM)
13.92%
Valuation
Price to earnings (TTM)
173.781
Price to revenue (TTM)
10.627
Price to book
14.58
Price to tangible book (TTM)
54.47
Price to free cash flow (TTM)
-1,523.874
Free cash flow yield (TTM)
-0.07%
Free cash flow per share (TTM)
-1.08%
Growth
Revenue change (TTM)
55.85%
Earnings per share change (TTM)
798.14%
3-year revenue growth (CAGR)
368.92%
3-year earnings per share growth (CAGR)
-20.27%
Bulls say / Bears say
Telix Pharmaceuticals' recent partnership with a leading oncology research institute is expected to accelerate the development of its radiopharmaceutical pipeline, potentially enhancing future revenue streams. (bloomberg.com)
The company's latest financial report indicates a 25% increase in quarterly revenue, driven by strong sales of its flagship diagnostic imaging agent. (reuters.com)
Telix has received FDA approval for its new prostate cancer imaging product, positioning it favorably in a growing market segment. (seekingalpha.com)
Regulatory challenges in key international markets have delayed the launch of Telix's new therapeutic products, potentially impacting projected revenues. (bloomberg.com)
Increased competition from larger pharmaceutical companies entering the radiopharmaceutical space may erode Telix's market share and pricing power. (reuters.com)
Recent clinical trial results for one of Telix's leading pipeline candidates did not meet primary endpoints, raising concerns about its future viability. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TLX News
AllArticlesVideos
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
GlobeNewsWire·2 weeks ago
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
GlobeNewsWire·2 weeks ago
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telix pharmaceutical stock?
Telix pharmaceutical (TLX) has a market cap of $5.5B as of July 04, 2025.
What is the P/E ratio for Telix pharmaceutical stock?
The price to earnings (P/E) ratio for Telix pharmaceutical (TLX) stock is 173.78 as of July 04, 2025.
Does Telix pharmaceutical stock pay dividends?
No, Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Telix pharmaceutical dividend payment date?
Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Telix pharmaceutical?
Telix pharmaceutical (TLX) has a beta rating of 2.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.